ClinicalTrials.gg

TargetBeta

GLP1R

glucagon like peptide 1 receptor · also GLP-1R · Glucagon receptor family

39 programs in company-led studies act on GLP1R, from 26 companies: 17 in phase 3, 4 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (22 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
TirzepatideruleEli Lillyphase 47220 runningGIPRChEMBL
SemaglutideruleNovo Nordiskphase 417018 running–NCIt
LiraglutideruleNovo Nordiskphase 41165 running–ChEMBL
dulaglutideruleEli Lillyphase 4471 running–NCIt
zenagamtideNovo Nordiskphase 33526 runningCALCRa judged reading
orforglipronruleEli Lillyphase 35017 running–the studies' text
berobenatidePfizerphase 32317 running–the company's pipeline
UBT251The United Laboratories Internationalphase 31212 runningGCGR, GIPRa judged reading
retatrutideruleEli Lillyphase 33311 runningGCGR, GIPRChEMBL
survodutideBoehringer Ingelheimphase 33510 runningGCGRthe company's pipeline
mazdutideruleInnovent Biologicsphase 3279 running–the studies' text
bofanglutideruleGan & Lee Pharmaceuticalsphase 3259 running–the studies' text
olatorepatideHansoh Pharmaceutical Groupphase 3127 runningGIPRa judged reading
enicepatideHoffmann-La Rochephase 3107 runningGIPRa judged reading
VK2735ruleViking Therapeuticsphase 385 runningGIPRthe studies' text
MDR-001ruleMindRank AIphase 365 running–the studies' text
DR10624ruleHuadong Medicinephase 364 runningGCGRthe studies' text
SafiglipronJiangsu HengRui Medicinephase 3193 running–the company's pipeline
efpeglenatideruleHanmi Pharmaceuticalphase 3131 running–ChEMBL
avexitideruleAmylyx Pharmaceuticalsphase 321 running–NCIt
edaglutide alfaCSPC Pharmaceutical Groupphase 3110 running–a judged reading
AZD9550AstraZenecaphase 275 runningGCGRa judged reading
BI 3034701Boehringer Ingelheimphase 264 runningGIPR, NPY2Rthe company's pipeline
HRS-4729Jiangsu HengRui Medicinephase 254 runningGCGR, GIPRthe company's pipeline
NNC0519-0130Novo Nordiskphase 2111 runningGIPRa judged reading
NA-931ruleBiomed Industriesphase 231 runningGIPR, IGF1the studies' text
TE-8105ruleImmunworkphase 221 running–the studies' text
danuglipronrulePfizerphase 2180 running–ChEMBL
efinopegdutideJohnson & Johnsonphase 2150 runningGCGRa judged reading
RGT001-075ruleRegor Pharmaceuticalsphase 230 running–the studies' text
TQF3250Sino Biopharmaceuticalphase 133 running–the company's pipeline
IBI3042ruleInnovent Biologicsphase 122 running–the studies' text
PF-08642534Pfizerphase 121 running–the company's pipeline
BLX-7006ruleBiolexis Therapeuticsphase 111 running–the studies' text
PF-08656795Pfizerphase 111 running–the company's pipeline
XTL6001ruleShanghai Xitaili Biomedicine Technologyphase 111 running–the studies' text
dapiglutideruleZealand Pharmaphase 140 running–the studies' text
BMF-650ruleBiomea Fusionphase 110 running–the studies' text
CagriSema ANovo Nordiskphase 110 runningCALCRa judged reading

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.